Welcome to our dedicated page for Verona Pharma news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma stock.
Verona Pharma plc was a respiratory biopharmaceutical company whose updates centered on Ohtuvayre (ensifentrine), a selective dual PDE3 and PDE4 inhibitor for maintenance treatment of chronic obstructive pulmonary disease in adults. Company news covered Ohtuvayre commercialization, analyses from the Phase 3 ENHANCE studies in COPD, respiratory-disease pipeline work including non-cystic fibrosis bronchiectasis, and financial results tied to the product launch.
Verona Pharma became a wholly owned subsidiary of Merck after the completed acquisition in 2025, and its American Depositary Shares ceased trading on the Nasdaq Global Market. Later corporate news reflects the completed status change, material agreements, shareholder voting matters, capital-structure disclosures, and governance matters.
Verona Pharma announced the initiation of its Phase 3 ENHANCE trials for nebulized ensifentrine, targeting patients with moderate to severe COPD. This pivotal study aims to demonstrate the efficacy and safety of ensifentrine, potentially paving the way for a New Drug Application in the U.S. if successful. Previous studies show ensifentrine's ability to improve lung function, symptoms, and quality of life in COPD patients. The ENHANCE trials will involve approximately 1,600 patients across the U.S. and Europe, assessing ensifentrine's effects over 24-48 weeks.
Verona Pharma announced the publication of a detailed analysis from a Phase 2b clinical trial of nebulized ensifentrine for COPD treatment in the International Journal of Chronic Obstructive Pulmonary Disease. The study, involving 405 patients, showed significant improvements in COPD symptoms within 4 weeks, notably in breathlessness, cough, and overall quality of life. Ensifentrine, a dual PDE3/PDE4 inhibitor, combines bronchodilation and anti-inflammatory effects. Positive outcomes from previous trials enhance its potential as a novel COPD therapy.
Verona Pharma (Nasdaq: VRNA) has initiated a pilot study to assess the efficacy and safety of ensifentrine delivered via a pressurized metered-dose inhaler (pMDI) in COVID-19 patients in the U.S. This randomized study will involve approximately 45 hospitalized patients, evaluating the compound's potential to improve recovery, clinical status, and reduce oxygen use. Ensifentrine has shown promise in previous trials for respiratory diseases, demonstrating improvements in lung function and safety. Successful outcomes could position ensifentrine as a novel COVID-19 treatment.
Verona Pharma (Nasdaq: VRNA) has announced that David Zaccardelli, CEO, will present a company overview at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 14, 2020, at 5:00 PM ET. A live webcast will be available on the company’s website, with an audio replay for 30 days. Verona Pharma focuses on respiratory diseases, with its lead product candidate, ensifentrine, aiming to combine bronchodilator and anti-inflammatory effects, with a Phase 3 program expected to start later in 2020.
Verona Pharma announced the grant of 6,794,521 Restricted American Depositary Share Units (RADSUs) to its directors and employees, representing 54,356,168 ordinary shares, or 13.11% of its total voting rights. The grants, made under the 2017 Incentive Award Plan, include notable allocations to CEO David Zaccardelli (1,785,203 RADSUs) and CFO Mark Hahn (1,916,861 RADSUs). Vesting schedules vary, with some shares set to vest incrementally over the next few years. The grants follow shareholder approval at the annual meeting on April 16, 2020, for additional share issuance authority.
Verona Pharma (VRNA) announced its presentation of new subgroup analysis from Phase 2b trials of nebulized ensifentrine for chronic obstructive pulmonary disease (COPD) at the European Respiratory Society (ERS) Congress on September 8, 2020. The analyses demonstrate significant improvements in lung function and quality of life for both reversible and non-reversible COPD patients, as compared to placebo. Ensifentrine, a dual PDE3/PDE4 inhibitor, also showed potential as a first-in-class therapy combining bronchodilation and anti-inflammatory effects. The company plans to initiate Phase 3 trials later in 2020.
Verona Pharma (Nasdaq: VRNA) has initiated the second part of a Phase 2 trial for ensifentrine, a treatment for moderate to severe COPD. Part B involves multiple dosing with results expected in H1 2021. The first part reported significant lung function improvement in 40 patients. Approximately 30 patients from Part A will advance to Part B, receiving three dose levels of ensifentrine or placebo. Ensifentrine has shown promise in prior studies, addressing unmet medical needs in the $9.6 billion COPD market.
Verona Pharma has completed a $200 million private placement to fund its clinical programs, including the Phase 3 trials of ensifentrine for COPD, scheduled to start later this year. The FDA has approved the company’s IND to initiate a pilot study for treating COVID-19 with ensifentrine. Despite a reported operating loss of £19.7 million ($24.4 million) for the first half of 2020, Verona Pharma's financial position remains strong, with net cash of £18.1 million ($22.4 million). The company continues to monitor COVID-19's impact on clinical trials, ensuring business continuity and safety for participants.